freeze-thaw cycle is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
The manifestation of apical dominance differs significantly between plant groups due to the positioning of their growing points (meristems): Broadleaf plants: The apical meristem is located at the shoot tip, elevated above the ground. Apical dominance is exerted downward, inhibiting axillary buds along the stem. Removing the apex (pruning) releases these buds, resulting in lateral branching and a bushier shape. Grasses: During vegetative growth, the primary apical meristem remains at or near the soil surface in a region called the crown. Growth occurs via intercalary meristems at the base of the leaves. Apical dominance in grasses primarily regulates tillering—the production of new shoots from basal buds. Because the meristem is protected at ground level, grasses can be mown or grazed without destroying the primary growing point, allowing them to recover more quickly than most broadleaf species. Plant physiologists have identified four different stages the plant goes through after the apex is removed (Stages I-IV). The four stages are referred to as:
Each fission of a parent atom produces a different set of fission product atoms. However, while an individual fission is not predictable, the fission products are statistically predictable. The amount of any particular isotope produced per fission is called its yield, typically expressed as percent per parent fission; therefore, yields total to 200%, not 100%. (The true total is in fact slightly greater than 200%, owing to rare cases of ternary fission.) While fission products include every element from zinc through the lanthanides, the majority of the fission products occur in two peaks. One peak occurs at about (expressed by atomic masses 85 through 105) strontium to ruthenium while the other peak is at about tellurium to neodymium (expressed by atomic masses 130 through 145). The yield is somewhat dependent on the parent atom and also on the energy of the initiating neutron. In general the higher the energy of the state that undergoes nuclear fission, the more likely that the two fission products have similar mass. Hence, as the neutron energy increases and/or the energy of the fissile atom increases, the valley between the two peaks becomes more shallow. For instance, the curve of yield against mass for 239Pu has a more shallow valley than that observed for 235U when the neutrons are thermal neutrons. The curves for the fission of the later actinides tend to make even more shallow valleys. In extreme cases such as 259Fm, only one peak is seen; this is a consequence of symmetric fission becoming dominant due to shell effects.
As more African-Americans are incarcerated, the more the heuristic is enforced in the eyes of the courts, which contributes to yet higher imprisonment rates among African-American children. High numbers of African American arrests and charges of possession show that although most drug users in the United States are white, blacks are the largest group being targeted as the root of the problem. Furthermore, a study by Andrew Golub, Bruce Johnson, and Eloise Dunlap affirms the racial divide in drug arrests, notably marijuana arrests, where blacks with no prior arrests (0.9%) or one prior arrest (4.3%) were nearly twice as likely to be sentenced to jail as their white counterparts (0.4% and 2.3%, respectively). Harboring such emotions can lead to a lack of will to contact the police in case of an emergency by members of African-American communities, ultimately leaving many people unprotected. Disproportionate arrests in African-American communities for drug-related offenses has not only spread fear but also perpetuated a deep distrust for government and what some call racist drug enforcement policy. Additionally, a black-white disparity can be seen in probation revocation since black probationers were revoked at higher rates than white and Hispanic probationers in studies as published under the Urban Institute.
Sources: en.wikipedia.org
== Use == Dipipanone is now unavailable in most countries of the world either by laws prohibiting its medicinal use as in the United States or by falling out of production as more modern analgesics took its market share. Great Britain, Northern Ireland and South Africa are known to continue to use the substance but it is infrequently prescribed. Dipipanone is a Schedule I controlled substance in the United States; it has been assigned the ACSCN of 9622 and since 2013 had an annual manufacturing quota of 5 grams.
The Bergmann degradation is a series of chemical reactions designed to remove a single amino acid from the carboxylic acid (C-terminal) end of a peptide. First demonstrated by Max Bergmann in 1934, it is a rarely used method for sequencing peptides. The later developed Edman degradation is an improvement upon the Bergmann degradation, instead cleaving the N-terminal amino acid of peptides to produce a hydantoin containing the desired amino acid. The Bergmann degradation follows the earlier work of Bergmann and his close colleague Leonidas Zervas, combining the organic azide degradation of the Curtius rearrangement with the Bergmann-Zervas carbobenzoxy method, which they designed to occur under relatively mild conditions so as to allow peptide sequencing. A single round of the Bergmann degradation yields an aldehyde containing the sought after amino acid residue and the remaining fragment of the original peptide in amide form.
It is a cyclin dependent kinase containing the catalytic subunit, Cdk9, and a regulatory subunit, cyclin T in Drosophila. In humans there are multiple forms of P-TEFb which contain Cdk9 and one of several cyclin subunits, cyclin T1, T2, and K. P-TEFb associates with other factors including the bromodomain protein BRD4, and is found associated with a large complex of proteins called the super elongation complex. Importantly, for the AIDS virus, HIV, P-TEFb is targeted by the HIV Tat protein which bypasses normal cellular P-TEFb control and directly brings P-TEFb to the promoter proximal paused polymerase in the HIV genome.
Sources: en.wikipedia.org
Limulus polyphemus, Atlantic horseshoe crab (2014) Carcinoscorpius rotundicauda, mangrove horseshoe crab (2021) Tachypleus gigas, coastal horseshoe crab (2020) Tachypleus tridentatus, tri-spine horseshoe crab (2021) Order Ixodida:
=== Generic names === Oxandrolone is the generic name of the drug and its INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, USPTooltip United States Pharmacopeia, BANTooltip British Approved Name, DCFTooltip Dénomination Commune Française, DCITTooltip Denominazione Comune Italiana, and JANTooltip Japanese Accepted Name, while ossandrolone is or was formerly the DCITTooltip Denominazione Comune Italiana.
== Other sources == Simoni RD, Hill RL, Vaughan M (August 2002). "Copper as an essential nutrient and nicotinic acid as the anti-black tongue (pellagra) factor: the work of Conrad Arnold Elvehjem". The Journal of Biological Chemistry. 277 (34): e22. doi:10.1016/S0021-9258(20)70109-2. ISSN 0021-9258. PMID 12185207. Elvehjem CA, Madden RJ, Strong FM, Woolley DW (February 1974). "The isolation and identification of the anti-black tongue factor". Nutrition Reviews. 32 (2): 48–50. doi:10.1111/j.1753-4887.1974.tb06263.x. ISSN 0029-6643. PMID 4274128. S2CID 7197859. Harper AE, Elvehjem CA (August 1991). "Journal of the American Medical Association, Volume 158, 1955: Importance of amino acid balance in nutrition". Nutrition Reviews. 49 (8): 233–4. doi:10.1111/j.1753-4887.1991.tb03034.x. ISSN 0029-6643. PMID 1956589. Burris RH, Baumann CA, Potter VR (1990). "Conrad Arnold Elvehjem: May 27, 1901 – July 27, 1962". Biographical Memoirs of the National Academy of Sciences. 59: 135–67. PMID 11616156. Todd W, Elvehjem C, Hart E (April 1980). "Zinc in the Nutrition of the Rat". Nutrition Reviews. 38 (4): 151–4. doi:10.1111/j.1753-4887.1980.tb05879.x. ISSN 0029-6643. PMID 7010227. Kline OL, Baumann CA (May 1971). "Conrad Arnold Elvehjem--a biographical sketch (1901–1962)". The Journal of Nutrition. 101 (5): 571–7. doi:10.1093/jn/101.5.569. ISSN 0022-3166. PMID 4930952.
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
Purity is normally expressed as a percentage of total peak area from a chromatographic run. The value depends on the column, gradient and detection wavelength chosen. Results generated under different conditions are therefore not always interchangeable.